Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
Adam Feuerstein
TheStreet, 3 June 2016
Immunomedics (IMMU) – Get Report was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting, which starts Friday.
Comment: Complete fraud. Stock went from $5.50 to $2.50 on millions of shares, then up to $27.
